

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	8587296
<b>Application Number:</b>	10803793
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5618
<b>Title of Invention:</b>	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
<b>First Named Inventor/Applicant Name:</b>	Erik Buntinx
<b>Customer Number:</b>	01912
<b>Filer:</b>	Alan Douglas Miller/Rosa Florio
<b>Filer Authorized By:</b>	Alan Douglas Miller
<b>Attorney Docket Number:</b>	29248/21
<b>Receipt Date:</b>	08-OCT-2010
<b>Filing Date:</b>	18-MAR-2004
<b>Time Stamp:</b>	11:33:34
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$470
RAM confirmation Number	19668
Deposit Account	011785
Authorized User	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	-------------------------------------	------------------	------------------

1	Request for Continued Examination (RCE)	1RCETrans.pdf	633566 e4eb61c0b5122a00f0b085c3571045e4c9902	no	3
<b>Warnings:</b>					
This is not a USPTO supplied RCE SB30 form.					
<b>Information:</b>					
2	Amendment After Final	2Amend.pdf	36160 1d22a2bae0b090216af0126a2b454377c103e0300	no	1
<b>Warnings:</b>					
<b>Information:</b>					
3	Claims	3Claims.pdf	31348 2693c7001d13575013c5e0b56cc5e64726fca7fc	no	4
<b>Warnings:</b>					
<b>Information:</b>					
4	Applicant Arguments/Remarks Made in an Amendment	4Remarks.pdf	33917 e711af918e853bd012b08461259a6892263ca7	no	3
<b>Warnings:</b>					
<b>Information:</b>					
5	Information Disclosure Statement (IDS) Filed (SB/08)	5IDS.pdf	1042280 3c19b00119710e70853d1136b126c5e13eb0ea9	no	5
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
6	NPL Documents	6Brown.pdf	150339 2f9ed5e75a3dbf0e70070134a0f4cd19f9d	no	10
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	7Caley.pdf	136320 b174700054067c07f9a30f20f3563e5ca30bb97	no	7
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	8Citalopram.pdf	968259 2f8b2baec71ac1762b4d40658147accca3512d0c30	no	2
<b>Warnings:</b>					
<b>Information:</b>					

9	NPL Documents	9Dierick.pdf	5549033 af16b4276afac2a3c93cb0f6f73fcb18-8c0b	no	15
Warnings:					
Information:					
10	NPL Documents	10Remington.pdf	3814293 4a4952ed65193150bc65dc492c28b312a3-60c0b	no	7
Warnings:					
Information:					
11	NPL Documents	11Stella.pdf	8869350 24c56ba35cd996a34217aabb1560c2b30055d2e	no	18
Warnings:					
Information:					
12	NPL Documents	12Hegerl.pdf	4617585 bc9f1b765d410922778065cd414d6ead6975db4	no	8
Warnings:					
Information:					
13	NPL Documents	13NOA06-23-10.pdf	1767891 31732f0db825d33dd1a7695a2affc57dce0f0	no	9
Warnings:					
Information:					
14	NPL Documents	14OA06-23-10.pdf	3753902 58c519edc37c6113435918fbc5d2979c37e57	no	22
Warnings:					
Information:					
15	NPL Documents	15OA03-18-10.pdf	3428905 41f38dd1cc448bc922d313564471709e2c092	no	20
Warnings:					
Information:					
16	NPL Documents	16OA04-14-10.pdf	3528646 b5b6ac8f559666640f818a9c3b1d813172ec073	no	20
Warnings:					
Information:					
17	NPL Documents	17NOA08-10-10.pdf	2927024 3d822471384f029fb19932c0b5c8a6942791c66	no	16
Warnings:					
Information:					

18	NPL Documents	18Buntinx.pdf	1742517 92140986246a678b73816e62958c018b20c34a	no	4
Warnings:					
Information:					
19	Fee Worksheet (PTO-875)	fee-info.pdf	31977 09577b1b40b1074c46941b9b41a726ff07251d8b	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			43063312		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					